As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus
Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.
You may also be interested in...
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
In this week's podcast edition of Five Must-Know Things: CAR-Ts move into earlier treatment; Sanofi bets big on super antibodies; takeaways from the world’s largest dermatology conference; China moves towards imported COVID vaccines; and R&D experts discuss the superbug threat.
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.